Drugs and Devices
by Jenna Ogilvie | Oct 22, 2018 | Commentary, Perspectives
Controlling or reducing the risk for cancer was a principal goal of the National Cancer Act, signed by President Nixon in 1971. Long before the human genome was sequenced, and the etiology of many cancers was understood, Americans were determined to find a way...
by Jenna Ogilvie | Oct 1, 2018 | Commentary, Perspectives
Upon arriving in Kenya in 1987, I was a well-trained parasitologist who knew nothing about development, economics, political systems, or structural poverty. Kenya, however, became my classroom. The focus three decades ago was to attack one disease at a time, to...
by Molly Doyle | Mar 19, 2018 | Discussion Paper, Perspectives
Emerging Opportunities for Digital Health Digital health technologies have emerged in recent years, providing opportunities for engaging with consumers and integrating with the health care system to realize precision medicine, defined as “an evidence-based...
by Kyra E. Cappelucci | Oct 9, 2017 | Discussion Paper, Perspectives
Climbing costs and lengthy time frames of clinical trials are significant bottlenecks in medical product development. Despite the fact that scientific discoveries yield many new possible targets for developing into therapies, the capacity and resources with which to...
by Kyra E. Cappelucci | Jul 31, 2017 | Discussion Paper, Perspectives
Antimicrobial Usage and Interventions: A Brief History from 1950 to the Present Antimicrobials for veterinary purposes came on the market in the 1950s, followed shortly by antimicrobial growth promoters (AGPs), because of their growth-enhancing effects to...
Page 2 of 8«12345...»Last »
